JP2025515337A - Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法 - Google Patents

Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法 Download PDF

Info

Publication number
JP2025515337A
JP2025515337A JP2024563361A JP2024563361A JP2025515337A JP 2025515337 A JP2025515337 A JP 2025515337A JP 2024563361 A JP2024563361 A JP 2024563361A JP 2024563361 A JP2024563361 A JP 2024563361A JP 2025515337 A JP2025515337 A JP 2025515337A
Authority
JP
Japan
Prior art keywords
btla
seq
binding agent
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515337A5 (enExample
Inventor
エドワード ダール、マーティン
パームリー、スティーブン
リズール、ポール
ヘア、エリック
Original Assignee
アナプティスバイオ インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アナプティスバイオ インコーポレイティッド filed Critical アナプティスバイオ インコーポレイティッド
Publication of JP2025515337A publication Critical patent/JP2025515337A/ja
Publication of JP2025515337A5 publication Critical patent/JP2025515337A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024563361A 2022-04-27 2023-04-26 Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法 Pending JP2025515337A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263335623P 2022-04-27 2022-04-27
US63/335,623 2022-04-27
PCT/US2023/066258 WO2023212611A1 (en) 2022-04-27 2023-04-26 B and t lymphocyte attenuator (btla) modulators and method of using same

Publications (2)

Publication Number Publication Date
JP2025515337A true JP2025515337A (ja) 2025-05-14
JP2025515337A5 JP2025515337A5 (enExample) 2026-05-11

Family

ID=86558778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563361A Pending JP2025515337A (ja) 2022-04-27 2023-04-26 Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法

Country Status (9)

Country Link
US (1) US20250282872A1 (enExample)
EP (1) EP4514850A1 (enExample)
JP (1) JP2025515337A (enExample)
KR (1) KR20250007603A (enExample)
AU (1) AU2023259623A1 (enExample)
CA (1) CA3256715A1 (enExample)
IL (1) IL316496A (enExample)
MX (1) MX2024013146A (enExample)
WO (1) WO2023212611A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004633A (es) * 2020-10-23 2023-05-12 Anaptysbio Inc Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
CA2769473A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
MX2023004633A (es) * 2020-10-23 2023-05-12 Anaptysbio Inc Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.

Also Published As

Publication number Publication date
WO2023212611A1 (en) 2023-11-02
IL316496A (en) 2024-12-01
CA3256715A1 (en) 2023-11-02
US20250282872A1 (en) 2025-09-11
KR20250007603A (ko) 2025-01-14
EP4514850A1 (en) 2025-03-05
MX2024013146A (es) 2025-01-09
AU2023259623A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
JP7212098B2 (ja) インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP6742903B2 (ja) プログラム死−１（ｐｄ−１）に対する抗体
JP7697106B2 (ja) Ｐｄ－１アゴニストおよびそれを使用する方法
US20250282872A1 (en) B and t lymphocyte attenuator (btla) modulators and method of using same
US20260062488A1 (en) Anti-alpha-4-beta-7 antibodies
US20220281990A1 (en) Anti-tnfr2 antibodies and uses thereof
US20230391872A1 (en) B and t lymphocyte attenuator (btla) modulators and method of using same
TW202216198A (zh) 使用抗組織因子抗體之炎性疾病治療
JP2025537224A (ja) Ｃｄ１２２結合剤およびその使用方法
EA053216B1 (ru) Модуляторы в- и т-лимфоцитарных аттенюаторов (btla) и способ их применения
CN116685603A (zh) B和t淋巴细胞衰减因子（btla）调节剂及其使用方法
HK40093375A (en) B and t lymphocyte attenuator (btla) modulators and method of using same
EA050223B1 (ru) Агонист pd-1 и способ его применения
RU2795625C2 (ru) Антигенсвязывающие белки против gitr и способы их применения
TW202342517A (zh) 使用抗組織因子抗體之炎性疾病治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260427